Showing all 3 results
The HER-2/NEU – FISH Test is a highly precise diagnostic tool used to detect HER-2 gene amplification in breast cancer and other malignancies. Utilizing Fluorescence In Situ Hybridization (FISH) technology, it provides accurate, reliable, and early detection of HER-2 status, which is crucial for determining targeted therapy eligibility, such as Herceptin (trastuzumab) treatment.
The PD-L1 (22C3) Dako CPS (IHC) test is an immunohistochemistry (IHC) assay designed to assess PD-L1 expression in tumor and immune cells using the Combined Positive Score (CPS). It is FDA-approved as a companion diagnostic for multiple cancer therapies, ensuring precise patient selection for immune checkpoint inhibitors. The test utilizes the 22C3 monoclonal antibody, providing high sensitivity and specificity in detecting PD-L1 expression. Its standardized scoring system (CPS) enhances reproducibility and clinical decision-making, making it a trusted tool for oncologists. The Dako platform ensures consistent, high-quality staining, supporting accurate and reliable results for personalized cancer treatment.
The **Ros1 – Fish Test** is a highly sensitive and reliable fluorescence in situ hybridization (FISH) assay designed for the detection of **ROS1 gene rearrangements** in tumor samples. This test is crucial for identifying patients who may benefit from targeted therapies, particularly in **non-small cell lung cancer (NSCLC)**. Key features include **high specificity and accuracy**, rapid turnaround time, and **direct visualization of gene rearrangements** at the cellular level. Its benefits include **early and precise diagnosis**, enabling personalized treatment decisions and improving patient outcomes. The **unique selling point** of the Ros1 – Fish Test is its **proven clinical utility in guiding targeted therapy selection**, making it an essential tool for oncologists and pathologists in precision medicine.
